{"id":15883,"date":"2021-12-14T13:15:04","date_gmt":"2021-12-14T13:15:04","guid":{"rendered":"https:\/\/incilab.az\/serologiya-testl%c9%99r-qrupu\/"},"modified":"2023-09-14T09:16:29","modified_gmt":"2023-09-14T09:16:29","slug":"group-of-serology-tests","status":"publish","type":"page","link":"https:\/\/incilab.az\/en\/group-of-serology-tests\/","title":{"rendered":"Group of serology tests"},"content":{"rendered":"

[vc_row][vc_column]

\r\n \r\n <\/div>\r\n
<\/div>
\r\n

ADENOV\u0130RUS ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>Kip qapaql\u0131 qabda, soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>10 g<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Lateks aqql\u00fctinasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMEB ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Entamoeba histoytica an\u00adticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>dolay\u0131 hemaqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ba\u011f\u0131rsaqdan k\u0259nar ame\u00adbiazlar\u0131n (x\u00fcsusil\u0259 qaraciy\u0259r absesi) t\u0259yinind\u0259 istifad\u0259 olunur. \u0130stifad\u0259 olunan \u00fcsulun spesifikliyi y\u00fcks\u0259k, h\u0259ssasl\u0131\u011f\u0131 d\u0259yi\u015fk\u0259ndir. Antici\u00adsim\u00adl\u0259\u00adrin y\u00fcks\u0259lm\u0259si qaraciy\u0259r\u00a0 absesl\u0259\u00adrind\u0259 100%, ameb dizenteriyalar\u0131nda is\u0259 98% m\u00fc\u015fahid\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMEB ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Entamoeba hystolytica an\u00adtigeni (H\u0259m\u00e7inin\u00a0 Bax N\u0259cisd\u0259 para\u00adzit antigenl\u0259ri)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Kip qapaql\u0131 qabda 24 saatdan gec olmayaraq, soyuq \u015f\u0259\u00adraitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 g<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HAV IGM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit A anticisimi IgM; HAV IgM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqaiv<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin HAV infeksiya\u00ads\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olu\u00adnur. 15-45 g\u00fcnl\u00fck inkubasiya d\u00f6v\u00adr\u00fcn\u00fc ke\u00e7dikd\u0259n sonra simptomlar\u0131n \u00fcz\u0259 \u00e7\u0131xmas\u0131 il\u0259 birlikd\u0259 qanda tap\u0131l\u0131r v\u0259 ad\u0259t\u0259n pozitivlik 3-6 ay davam edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HAV TOTAL (IGM + IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit A anticisiml\u0259ri\u2013 total;\u00a0 HAV total<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>3 saat<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqaiv<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatit A-ya qar\u015f\u0131 immunitetin olub-olmad\u0131\u011f\u0131n\u0131n qiy\u00adm\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HBC IGM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit B virusu \u00f6z\u0259k (core) anticisimi IgM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin HBV infek\u00adsi\u00adya\u00adlar\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olu\u00adnur. Simptomlar\u0131n \u00fcz\u0259 \u00e7\u0131xmas\u0131 il\u0259 b\u0259rab\u0259r qanda tap\u0131l\u0131r. P\u0259nc\u0259r\u0259 d\u00f6v\u00adr\u00fcnd\u0259 serumda tap\u0131lan yegan\u0259 g\u00f6s\u00adt\u0259rici oldu\u011fundan, bu d\u00f6vrd\u0259ki x\u0259s\u00adt\u0259l\u0259rin qiym\u0259tl\u0259ndirilm\u0259si \u00fc\u00e7\u00fcn x\u00fc\u00adsusi \u0259h\u0259miyy\u0259t k\u0259sb edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HBC TOTAL (IGM + IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit B virusu \u00f6z\u0259k (core) anticisiml\u0259ri-total<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u018fvv\u0259ll\u0259r HBV infeksi\u00adya\u00ads\u0131n\u0131n ke\u00e7irilib-ke\u00e7irilm\u0259diyi haqq\u0131n\u00adda m\u0259lumat verir. Anti-HBc IgM il\u0259 birlikd\u0259 k\u0259skin\/xroniki HBV infek\u00adsi\u00adyas\u0131n\u0131n diferensial diaqnozu \u00fc\u00e7\u00fcn qiym\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HBE<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit B virusu e anti\u00adcisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0HBV infeksiyas\u0131n\u0131n m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. HBeAg itdikd\u0259n sonra serumda tap\u0131l\u0131r. Anti-Hbe pozitiv olan xroniki da\u015f\u0131y\u0131\u00adc\u0131\u00adla\u00adr\u0131n qaraciy\u0259rinin h\u0259m histoloji m\u00fca\u00adyi\u00adn\u0259sinin n\u0259tic\u0259l\u0259ri, h\u0259m d\u0259 funk\u00adsional testl\u0259ri ad\u0259t\u0259n normal olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HBS<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbsAb; Hepatit B-nin s\u0259thi antigenin\u0259 qar\u015f\u0131 anticisiml\u0259r; Hepatit B s anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HBV-y\u0259 qar\u015f\u0131 immu\u00adni\u00adtetin t\u0259yinind\u0259 istifad\u0259 olunur. HBV infek\u00adsiyas\u0131n\u0131n bitm\u0259si il\u0259 b\u0259rab\u0259r (HBsAg itdikd\u0259n sonra) anti-HBs \u0259m\u0259l\u0259 g\u0259lir. H\u0259m\u00e7inin HBV-y\u0259 qar\u015f\u0131 immuni\u00adza\u00adsi\u00adyadan (vaksinasiya) son\u00adra immunitetin t\u0259yinind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HCV<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit C anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0HCV infeksiyas\u0131n\u0131n diaq\u00adnos\u00adtikas\u0131nda istifad\u0259 olunur. Ad\u0259t\u0259n HCV infeksiyas\u0131n\u0131n sonrak\u0131 (gec) d\u00f6vr\u00adl\u0259rind\u0259 qanda tap\u0131l\u0131r. Qanda An\u00adti-HCV-nin m\u00f6vcud olmas\u0131 inmmu\u00adni\u00adteti t\u0259min etmir. Pozitiv n\u0259tic\u0259l\u0259r di\u00adg\u0259r m\u00fcayin\u0259 \u00fcsullar\u0131 il\u0259 t\u0259sdiq\u00adl\u0259n\u00adm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HDV<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta anticisimi; Anti-Delta ; Hepatit D virusu anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HDV infeksiyas\u0131n\u0131n diaq\u00adnostikas\u0131nda istifad\u0259 olunur. X\u00fcsu\u00adsil\u0259 stabil xroniki HBV infeksiyas\u0131 olanlarda ani k\u0259skinl\u0259\u015fm\u0259 ba\u015f ver\u00addik\u00add\u0259 delta anticisiminin varl\u0131\u011f\u0131 ara\u015f\u00add\u0131r\u0131lmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BORREL\u0130A BURGDORFER\u0130 ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Lyme screen (total anticisim)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si.<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Borrelia burqdorferi<\/em>-nin s\u0259b\u0259b oldu\u011fu Lyme x\u0259st\u0259liyinin diaqnozunda istifad\u0259 olunur. X\u0259st\u0259liyin ilkin m\u0259rh\u0259l\u0259sind\u0259 yalan\u00e7\u0131 neqativlik ola bil\u0259r. Anticisiml\u0259rin t\u0259dqiqind\u0259 ilkin n\u0259tic\u0259l\u0259rin neqativ olmas\u0131na baxmayaraq, x\u0259st\u0259liyin ba\u015flan\u011f\u0131c m\u0259rh\u0259l\u0259d\u0259 oldu\u011fu d\u00fc\u015f\u00fc\u00adn\u00fcl\u00fcrs\u0259, 2-4 h\u0259ft\u0259 sonra yeni qan n\u00fcmun\u0259si il\u0259 test t\u0259krarlanmal\u0131d\u0131r. Pozitiv n\u0259tic\u0259l\u0259r is\u0259 Western blot il\u0259 d\u0259qiql\u0259\u015fdirilm\u0259lidir. Sifilis, HIV v\u0259 hiperqammaqlobulinemiya da antici\u00adsim testind\u0259 yalan\u00e7\u0131 pozitivlikl\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BORREL\u0130A BURGDORFER\u0130 WESTERN BLOT IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Lyme x\u0259st\u0259liyi western blot<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Western blot<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Lyme x\u0259st\u0259liyinin diaq\u00adnozunda ilk n\u00f6vb\u0259d\u0259 skrininq test il\u0259 total anticisiml\u0259rin axtar\u0131lmas\u0131, s\u0259r\u00adh\u0259d\u0259 yax\u0131n v\u0259 ya pozitiv n\u0259tic\u0259l\u0259rin is\u0259 western blot il\u0259 t\u0259sdiql\u0259nm\u0259si t\u00f6vsiy\u0259 olunur. Erk\u0259n m\u0259rh\u0259l\u0259d\u0259 is\u0259 x\u0259st\u0259liyin diaqnozunda birba\u015fa wes\u00adtern blot \u00fcsulu istifad\u0259 oluna bil\u0259r. Bu halda neqativ n\u0259tic\u0259 al\u0131narsa v\u0259 klinik \u015f\u00fcbh\u0259 davam ed\u0259rs\u0259 2-4 h\u0259ft\u0259 sonra test t\u0259krarlanmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA ANT\u0130HUMAN QLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kon\u00adtaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Xroniki brusellyoz za\u00adman\u0131 IgG tipli natamam (blok edici) anticisiml\u0259ri t\u0259yin edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA AQQL\u00dcT\u0130NAS\u0130YA TEST\u0130 (BRUCELLA RAYT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Brucella aqql\u00fctinasiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Brusellyoz x\u0259st\u0259liyinin diaqnozunda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA AQQL\u00dcT\u0130NAS\u0130YA TEST\u0130 (BRUCELLA RAYT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Brucella aqql\u00fctinasiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Brusellyoz x\u0259st\u0259liyinin diaqnozunda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA IGM<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a02-ME reduksiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Brucella IgM antici\u00adsiml\u0259rinin t\u0259yinind\u0259 istifad\u0259 olunur.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA RAYT (WRIGHT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Brucella aqql\u00fctinasiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Brusellyoz x\u0259st\u0259liyinin diaqnozunda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA SKR\u0130N\u0130NQ (ROSE-BENGAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Brucella slide testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si( BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Brusellyoz x\u0259st\u0259liyinin diaqnozunda skrininq test kimi istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BRUCELLA SLIDE TEST (BRUCELLA SKR\u0130N\u0130NQ ROSE-BENGAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Brucella slide testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si( BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Brusellyoz x\u0259st\u0259liyinin diaqnozunda skrininq test kimi istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CHLAMYDIA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFR<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qad\u0131nlarda\u00a0 servisit, \u00e7a\u00adnaq orqanlar\u0131n\u0131n iltihabi x\u0259st\u0259likl\u0259ri, en\u00addo\u00admetrit, perihepatit v\u0259 uretral sin\u00addroma; ki\u015fil\u0259rd\u0259 qeyri-qonokok etiologiyal\u0131 uretrit v\u0259 epididemit\u0259; yeni do\u011fulan\u00adlarda is\u0259 konyunktivit v\u0259 pnevmo\u00adni\u00adyaya s\u0259b\u0259b olan bak\u00adteriyaya qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n immuni\u00adtetin t\u0259yinind\u0259 istifad\u0259 olunur. H\u0259m\u00ad\u00e7inin\u00a0Chlamydia pneumonia\u00a0<\/em>v\u0259\u00a0psittaci<\/em>-y\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n im\u00admuniteti g\u00f6st\u0259rir. Xlamidiya infek\u00adsi\u00adyas\u0131n\u0131n seroloji \u00fcsulla t\u0259yini; xla\u00admi\u00addiya n\u00f6vl\u0259ri aras\u0131nda \u00e7arpaz reaktiv anticisiml\u0259rin varl\u0131\u011f\u0131n\u0131n, anti-xla\u00admi\u00addiya anticisiml\u0259rinin qeyri-spe\u00adsifik stimulyasiyas\u0131n\u0131n v\u0259 ya qar\u0131\u015f\u0131q xla\u00admi\u00addiya n\u00f6vl\u0259ri il\u0259 \u0259vv\u0259ll\u0259r qar\u015f\u0131\u00adla\u015f\u00adman\u0131n a\u011f\u0131rla\u015fmas\u0131 ola bil\u0259r. B\u00f6\u00ady\u00fck\u00adl\u0259r\u00add\u0259 anticisim pozitivliyi 50-78% ara\u00ads\u0131nda d\u0259yi\u015fir. X\u00fcsusil\u0259 IgM-d\u0259 \u00e7araz reaksiya daha \u00e7ox m\u00fc\u015fahid\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CLOSTR\u0130D\u0130UM D\u0130FF\u0130C\u0130LE TOKS\u0130N A<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Psevdomembranoz kolit seroloji testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a020 g<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Clostridium difficile<\/em>,an\u00adtibiotik q\u0259bulu il\u0259 \u0259laq\u0259dar ishal v\u0259 psevdomembranoz kolit\u0259 s\u0259b\u0259b olur. Eyni zamanda A v\u0259 B toksini adlan\u00add\u0131r\u0131lan iki toksin ifraz edir. A toksini maye itkisi, selikli qi\u015falarda z\u0259d\u0259\u00adl\u0259nm\u0259 v\u0259 ba\u011f\u0131rsaq iltihab\u0131na s\u0259b\u0259b olur. A toksininin n\u0259cisd\u0259 tap\u0131lmas\u0131 il\u0259 m\u00f6vcud ishal\u0131n s\u0259b\u0259bi m\u0259lum olur. \u0130shal\u0131n ba\u015flamas\u0131ndan \u0259vv\u0259lki son 8 h\u0259ft\u0259 m\u00fcdd\u0259tind\u0259 antibiotik is\u00adtifad\u0259 ed\u0259nl\u0259r m\u00fctl\u0259q m\u00fcayin\u0259 olunmal\u0131d\u0131rlar. Bir \u00e7ox hallarda\u00a0Clostridium difficile<\/em>\u00a0da\u015f\u0131y\u0131c\u0131l\u0131\u011f\u0131na da rast g\u0259linir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CMV IGG AV\u0130DL\u0130K<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Cytomegalovirus IgG avidite<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0CMV infeksiyas\u0131n\u0131n\u00a0 d\u00f6l\u0259 t\u0259sir edib-etm\u0259m\u0259sinin m\u00fc\u0259yy\u0259n edilm\u0259sind\u0259 istifad\u0259 olunur. CMV infeksiyas\u0131n\u0131n t\u0259xmini ba\u015flan\u011f\u0131c tarixi haqq\u0131nda informasiya verir. Bel\u0259likl\u0259 birincili infeksiyan\u0131n hamil\u0259lik m\u00fcdd\u0259tind\u0259 ba\u015f verib-verm\u0259diyi, ba\u015fqa s\u00f6zl\u0259, d\u00f6l\u00fcn CMV infeksiyas\u0131 il\u0259 z\u0259d\u0259l\u0259nm\u0259 ehtimal\u0131n\u0131n varl\u0131\u011f\u0131 qiym\u0259tl\u0259ndirilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CMV IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Cytomegalovirus IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL (serum), 100 \u03bcL (BOM)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA (serum), \u0130FR (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0CMV infeksiyas\u0131 ad\u0259t\u0259n asimptomatik ke\u00e7ir. Transplantasiya x\u0259st\u0259l\u0259ri, x\u0259r\u00e7\u0259ng x\u0259st\u0259l\u0259ri v\u0259 im\u00admun reaktivliyi z\u0259ifl\u0259mi\u015f x\u0259st\u0259l\u0259rd\u0259 is\u0259 a\u011f\u0131r hepatit v\u0259 retinit infek\u00adsi\u00adyalar\u0131 m\u00fc\u015fahid\u0259 oluna bil\u0259r. \u0130m\u00admun\u00adsupressiv x\u0259st\u0259l\u0259r CMV infeksi\u00adyas\u0131na \u0259sas\u0259n hemotransfuziya il\u0259 yoluxur. Buna g\u00f6r\u0259 d\u0259, bel\u0259 x\u0259st\u0259l\u0259r\u0259 veril\u0259c\u0259k qan n\u00fcmun\u0259l\u0259rini CMV infeksiyas\u0131na g\u00f6r\u0259 yoxlan\u0131lmal\u0131d\u0131r. Bundan ba\u015fqa, \u0259n \u00e7ox rast g\u0259lin\u0259n anadang\u0259lm\u0259 virus infeksiyas\u0131 oldu\u00ad\u011fundan hamil\u0259l\u0259rd\u0259 d\u0259 yoxlan\u0131lmas\u0131 vacibdir. Anan\u0131n IgG anticisimil\u0259ri d\u00f6l \u00fc\u00e7\u00fcn qoruyucu deyil v\u0259 CMV infeksiyas\u0131 d\u00f6ld\u0259 q\u00fcsurlara s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CRYPTOSPOR\u0130D\u0130UM ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Kip qapaql\u0131 bir qabda \u0259n gec 24 saat m\u00fcdd\u0259tind\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 g<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CYTOMEGALOV\u0130RUS IGG AV\u0130D\u0130TE (CMV IGG AV\u0130DL\u0130K)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Cytomegalovirus IgG avidite<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0CMV infeksiyas\u0131n\u0131n\u00a0 d\u00f6l\u0259 t\u0259sir edib-etm\u0259m\u0259sinin m\u00fc\u0259yy\u0259n edilm\u0259sind\u0259 istifad\u0259 olunur. CMV infeksiyas\u0131n\u0131n t\u0259xmini ba\u015flan\u011f\u0131c tarixi haqq\u0131nda informasiya verir. Bel\u0259likl\u0259 birincili infeksiyan\u0131n hamil\u0259lik m\u00fcdd\u0259tind\u0259 ba\u015f verib-verm\u0259diyi, ba\u015fqa s\u00f6zl\u0259, d\u00f6l\u00fcn CMV infeksiyas\u0131 il\u0259 z\u0259d\u0259l\u0259nm\u0259 ehtimal\u0131n\u0131n varl\u0131\u011f\u0131 qiym\u0259tl\u0259ndirilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CYTOMEGALOV\u0130RUS IGM V\u018f IGG (CMV IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Cytomegalovirus IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL (serum), 100 \u03bcL (BOM)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA (serum), \u0130FR (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0CMV infeksiyas\u0131 ad\u0259t\u0259n asimptomatik ke\u00e7ir. Transplantasiya x\u0259st\u0259l\u0259ri, x\u0259r\u00e7\u0259ng x\u0259st\u0259l\u0259ri v\u0259 im\u00admun reaktivliyi z\u0259ifl\u0259mi\u015f x\u0259st\u0259l\u0259rd\u0259 is\u0259 a\u011f\u0131r hepatit v\u0259 retinit infek\u00adsi\u00adyalar\u0131 m\u00fc\u015fahid\u0259 oluna bil\u0259r. \u0130m\u00admun\u00adsupressiv x\u0259st\u0259l\u0259r CMV infeksi\u00adyas\u0131na \u0259sas\u0259n hemotransfuziya il\u0259 yoluxur. Buna g\u00f6r\u0259 d\u0259, bel\u0259 x\u0259st\u0259l\u0259r\u0259 veril\u0259c\u0259k qan n\u00fcmun\u0259l\u0259rini CMV infeksiyas\u0131na g\u00f6r\u0259 yoxlan\u0131lmal\u0131d\u0131r. Bundan ba\u015fqa, \u0259n \u00e7ox rast g\u0259lin\u0259n anadang\u0259lm\u0259 virus infeksiyas\u0131 oldu\u00ad\u011fundan hamil\u0259l\u0259rd\u0259 d\u0259 yoxlan\u0131lmas\u0131 vacibdir. Anan\u0131n IgG anticisimil\u0259ri d\u00f6l \u00fc\u00e7\u00fcn qoruyucu deyil v\u0259 CMV infeksiyas\u0131 d\u00f6ld\u0259 q\u00fcsurlara s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DELTA ANT\u0130C\u0130S\u0130M\u0130 (HEPAT\u0130T D V\u0130RUS ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta anticisimi; Anti-Delta ; Hepatit D virusu anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HDV infeksiyas\u0131n\u0131n diaq\u00adnostikas\u0131nda istifad\u0259 olunur. X\u00fcsu\u00adsil\u0259 stabil xroniki HBV infeksiyas\u0131 olanlarda ani k\u0259skinl\u0259\u015fm\u0259 ba\u015f ver\u00addik\u00add\u0259 delta anticisiminin varl\u0131\u011f\u0131 ara\u015f\u00add\u0131r\u0131lmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u00dcZ (B\u0130RBA\u015eA) STREP A TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Strep A antigen testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u018fsn\u0259k material\u0131<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Steril tamponlu s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunoxromatoqrafik<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>A qrupundan olan beta hemolitik streptokoklar\u0131n antigen x\u00fcsusiyy\u0259tl\u0259ri \u0259sas g\u00f6t\u00fcr\u00fcl\u0259r\u0259k bu bakteriyalar t\u0259yin olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EBV EA ANT\u0130C\u0130S\u0130M\u0130 (EBV IGM V\u018f IGG PROF\u0130LL\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EBV EBNA ANT\u0130C\u0130S\u0130M\u0130 (EBV IGM V\u018f IGG PROF\u0130LL\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EBV IGM V\u018f IGG PROF\u0130LL\u018fR\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EBV VCA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 (EBV IGM V\u018f IGG PROF\u0130LL\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ECH\u0130NOCOCCUS SEROLOJ\u0130 TEST\u0130 (K\u0130ST H\u0130DAT\u0130K DOLAYI HEMAQQL\u00dcT\u0130NAS\u0130YA TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Echinococcus seroloji testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Aqql\u00fctinasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Exinokokkoz x\u0259st\u0259liyi \u00fc\u00e7\u00fcn seroloji skrininq testi kimi is\u00adtifad\u0259 olunur. X\u0259st\u0259y\u0259 dair anam\u00adnestik m\u0259lumatlar, klinik simptomlar v\u0259 radioloji m\u0259lumatlara \u0259sas\u0259n diaq\u00adnoz m\u00fc\u0259yy\u0259n edilir. Kollagen to\u00adxuma x\u0259st\u0259likl\u0259ri, sirroz, \u015fisto\u00adsomoz v\u0259 dig\u0259r parazitar infeksiyalar yalan\u00e7\u0131 pozitivlikl\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ECH\u0130NOCOCCUS SPES\u0130K\u0130K IGE (K\u0130ST H\u0130DAT\u0130K SPES\u0130F\u0130K IGE)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Echinococcus spesifik IgE<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>FEIA<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Exinokokoz x\u0259st\u0259liyinin diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ENTAMOEBA HYSTOL\u0130T\u0130CA ANT\u0130C\u0130S\u0130M\u0130 (AMEB ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Entamoeba histoytica an\u00adticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>dolay\u0131 hemaqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Ba\u011f\u0131rsaqdan k\u0259nar ame\u00adbiazlar\u0131n (x\u00fcsusil\u0259 qaraciy\u0259r absesi) t\u0259yinind\u0259 istifad\u0259 olunur. \u0130stifad\u0259 olunan \u00fcsulun spesifikliyi y\u00fcks\u0259k, h\u0259ssasl\u0131\u011f\u0131 d\u0259yi\u015fk\u0259ndir. Antici\u00adsim\u00adl\u0259\u00adrin y\u00fcks\u0259lm\u0259si qaraciy\u0259r\u00a0 absesl\u0259\u00adrind\u0259 100%, ameb dizenteriyalar\u0131nda is\u0259 98% m\u00fc\u015fahid\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EPSTEIN-BARR V\u0130RUSU ERK\u018fN ANT\u0130GEN ANT\u0130C\u0130S\u0130M\u0130 (EBV IGM V\u018f IGG ANT\u0130C\u0130S\u0130ML\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EPSTEIN-BARR V\u0130RUSU KAPS\u0130D ANT\u0130GEN ANT\u0130C\u0130S\u0130M\u0130 (EBV IGM V\u018f IGG ANT\u0130C\u0130S\u0130ML\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EPSTEIN-BARR V\u0130RUSU NUKLEAR ANT\u0130GEN ANT\u0130C\u0130S\u0130M\u0130 (EBV IGM V\u018f IGG ANT\u0130C\u0130S\u0130ML\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

Testin t\u0259rkibi:\u00a0<\/strong>VCA gp 125,VCA p19, EBNA-1, p22 v\u0259 EA-D<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Immunobolt<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>EBV infeksiyas\u0131 geni\u015f ya\u00ady\u0131lsa da, u\u015faqlarda ilkin infeksiya ad\u0259t\u0259n asimptomatik ke\u00e7ir. Sonrak\u0131 ya\u015f d\u00f6vrl\u0259rind\u0259 is\u0259 infeksion mono\u00adnukleoz klinikas\u0131 meydana \u00e7\u0131x\u0131r. C\u0259miyy\u0259td\u0259 insanlar\u0131n ya\u015fad\u0131\u011f\u0131\u0131 m\u00fcdd\u0259t \u0259rzind\u0259 EBV infeksiyas\u0131 ke\u00e7irm\u0259 ehtimal\u0131 90%-d\u0259n \u00e7oxdur. EBV infeksiyas\u0131n\u0131n diaqnozunu m\u00fc\u00ad\u0259yy\u0259n etm\u0259k b\u0259z\u0259n \u00e7ox \u00e7\u0259tin olur. Diaqnostikas\u0131nda seroloji \u00fcsullardan dah \u00e7ox istifad\u0259 olunur. Bu testl\u0259r h\u0259r zaman x\u0259st\u0259nin klinik \u0259lam\u0259tl\u0259ri n\u0259z\u0259r\u0259 al\u0131naraq qiym\u0259tl\u0259n\u00addiril\u00adm\u0259li\u00addir. Burkitt limfomas\u0131 v\u0259 nazofa\u00adrin\u00adgeal karsinomada anticisim s\u0259viy\u00ady\u0259l\u0259ri uzun m\u00fcdd\u0259t y\u00fcks\u0259k qala bil\u0259r.<\/p>\n\n\n\n\n\n\n\n\n
Klinik m\u0259rh\u0259l\u0259<\/td>\nHeterofil anticisim<\/td>\nVCA IgM<\/td>\nVVA IgG<\/td>\nEBNA<\/td>\nEA (D)<\/td>\n<\/tr>\n
\u015e\u00fcbh\u0259li<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
\u00c7ox erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+\/-<\/td>\n+\/-<\/td>\n+\/-<\/td>\n\u2013<\/td>\n\u2013<\/td>\n<\/tr>\n
Erk\u0259n m\u0259rh\u0259l\u0259<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n\u2013<\/td>\n+\/-<\/td>\n<\/tr>\n
M\u00f6vcud infeksiya<\/td>\n+<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n+\/-<\/td>\n<\/tr>\n
Ke\u00e7irilmi\u015f infeksiya<\/td>\n\u2013<\/td>\n\u2013<\/td>\n+<\/td>\n+<\/td>\n+\/-<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FORMOL GEL<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ley\u015fmaniozun diaq\u00adno\u00adzunda istifad\u0259 olunan qeyri spesifik testdir. Qamma-qlobulinl\u0259rin artmas\u0131 il\u0259 pozitivl\u0259\u015fdiyi \u00fc\u00e7\u00fcn diaqnoz m\u0259q\u00ads\u0259dil\u0259 deyil, diaqnozu d\u0259st\u0259kl\u0259y\u0259n test kimi istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FTA-ABS<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Fl\u00fcoressent treponemal anticisim-absorbsiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u00ad\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130FR<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Sifilisin diaqnostikas\u0131nda istifad\u0259 olunur. Treponema pallidum \u00fc\u00e7\u00fcn spesifik testl\u0259rd\u0259n biridir. SLE, hamil\u0259lik v\u0259 c\u00fczam yalan\u00e7\u0131 pozi\u00adtivliy\u0259 s\u0259b\u0259b ola bil\u0259r. M\u00fcalic\u0259d\u0259n sonra pozitiv qald\u0131\u011f\u0131ndan m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunmur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

G\u0130AR\u0130DA ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0S\u0131zd\u0131rmayan qapaql\u0131 bir qabda \u0259n gec 24 saat \u0259rzind\u0259, soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidi<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>10 g<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GRUBER-W\u0130DAL TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qar\u0131n yatala\u011f\u0131 v\u0259 paratif infeksiyalar\u0131 zaman\u0131 O aqql\u00fc\u00adtininl\u0259ri 8-ci g\u00fcnd\u0259n, H aqql\u00fctininl\u0259ri is\u0259 10-12-ci g\u00fcnd\u0259n sonra t\u0259yin oluna bil\u0259n s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. K\u0259skin x\u0259st\u0259liyin t\u0259yini \u00fc\u00e7\u00fcn 10-15 g\u00fcn fasil\u0259 il\u0259 al\u0131nan qan n\u00fcmun\u0259l\u0259rind\u0259 titr art\u0131m\u0131 m\u00fc\u015fahid\u0259 olunmal\u0131d\u0131r. Yaln\u0131z H aqql\u00fctininin olmas\u0131 vaksinasiyan\u0131, O is\u0259 x\u0259st\u0259liyi bildirir. Erk\u0259n m\u0259r\u00adh\u0259\u00adl\u0259d\u0259 m\u00fcalic\u0259y\u0259 ba\u015flan\u0131lan hallarda pozitivlik m\u00fc\u015fahid\u0259 olunmaya bil\u0259r. D\u0259qiq diaqnoz \u00fc\u00e7\u00fcn bu test t\u0259k\u00adba\u00ad\u015f\u0131na yet\u0259rli deyil. Qeyri-spesifik reak\u00adsiyalara da rast g\u0259lin\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HAV IGM (ANT\u0130-HAV IGM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit A anticisimi IgM; HAV IgM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqaiv<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin HAV infeksiya\u00ads\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olu\u00adnur. 15-45 g\u00fcnl\u00fck inkubasiya d\u00f6v\u00adr\u00fcn\u00fc ke\u00e7dikd\u0259n sonra simptomlar\u0131n \u00fcz\u0259 \u00e7\u0131xmas\u0131 il\u0259 birlikd\u0259 qanda tap\u0131l\u0131r v\u0259 ad\u0259t\u0259n pozitivlik 3-6 ay davam edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HAV TOTAL (ANT\u0130-HAV TOTAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit A anticisiml\u0259ri\u2013 total;\u00a0 HAV total<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>3 saat<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqaiv<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatit A-ya qar\u015f\u0131 immunitetin olub-olmad\u0131\u011f\u0131n\u0131n qiy\u00adm\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunu<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HBEAG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u00a0Hepatit Be antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HBV infeksiyas\u0131n\u0131n m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. \u0130nfek\u00adsi\u00adyan\u0131n erk\u0259n d\u00f6vrl\u0259rind\u0259, HBsAg-d\u0259n sonra meydana \u00e7\u0131x\u0131r. Virusda aktiv vi\u00adrus replikasiyas\u0131n\u0131n oldu\u011funu g\u00f6s\u00adt\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HBSAB (ANT\u0130-HBS)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbsAb; Hepatit B-nin s\u0259thi antigenin\u0259 qar\u015f\u0131 anticisiml\u0259r; Hepatit B s anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HBV-y\u0259 qar\u015f\u0131 immu\u00adni\u00adtetin t\u0259yinind\u0259 istifad\u0259 olunur. HBV infek\u00adsiyas\u0131n\u0131n bitm\u0259si il\u0259 b\u0259rab\u0259r (HBsAg itdikd\u0259n sonra) anti-HBs \u0259m\u0259l\u0259 g\u0259lir. H\u0259m\u00e7inin HBV-y\u0259 qar\u015f\u0131 immuni\u00adza\u00adsi\u00adyadan (vaksinasiya) son\u00adra immunitetin t\u0259yinind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HBSAG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hepatit B s\u0259thi (surface) antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya xroniki HBV infeksiyalar\u0131n\u0131n t\u0259yinind\u0259 isti\u00adfad\u0259 olunur. HBV infeksiyas\u0131 zaman\u0131 serumda a\u015fkara \u00e7\u0131xan ilk seroloji markerdir (6-16-c\u0131 h\u0259ft\u0259). K\u0259skin in\u00adfeksiyalarda \u0259sas\u0259n simptomlar it\u00addik\u00ad\u00ad\u00add\u0259n 1-2 ay sonra yox olur. HBsAg-nin 6 aydan \u00e7ox qalmas\u0131 xro\u00ad\u00adniki da\u015f\u0131y\u0131c\u0131l\u0131q v\u0259 ya xroniki qa\u00adraciy\u0259r x\u0259st\u0259liyinin g\u00f6st\u0259ricisidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HBSAG T\u018fSDIQL\u018fM\u018f TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatit B infeksiyas\u0131 zaman\u0131, HBsAg ad\u0259t\u0259n klinik simptomlar\u0131n meydan \u00e7\u0131xmas\u0131ndan 2-8 h\u0259ft\u0259 \u0259vv\u0259l t\u0259yin oluna bil\u0259c\u0259k s\u0259viyy\u0259y\u0259 \u00e7at\u0131r v\u0259 2-3 ay \u0259rzind\u0259 pozitiv qal\u0131r. Bununla birlikd\u0259, HBsAg pozitiv hallar\u0131n t\u0259xmin\u0259n 5 %-i yalan\u00e7\u0131 pozitivlikl\u0259 \u0259laq\u0259dard\u0131r v\u0259 t\u0259sdiql\u0259m\u0259 testi il\u0259 neqativ n\u0259tic\u0259 \u0259ld\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEL\u0130COBACTER PYLOR\u0130 ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGA V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300\u00a0 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>H.pylori infeksiyas\u0131n\u0131n di\u00adaq\u00adnozunda istifad\u0259 edil\u0259n qeyri-invazif testl\u0259rdir. M\u00fcalic\u0259d\u0259n son\u00adrak\u0131 6-8 ay \u0259rzind\u0259 anticisim s\u0259viy\u00ady\u0259sinin d\u00fc\u015fm\u0259si m\u00fc\u015fahid\u0259 edilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEL\u0130COBACTER PYLOR\u0130 ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HpSA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a020 g (qoz b\u00f6y\u00fck\u00adl\u00fcy\u00fcnd\u0259)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00f6y\u00fckl\u0259rd\u0259 H.pylorinin t\u0259\u00adyini v\u0259 m\u00fcalic\u0259d\u0259n sonrak\u0131 eradi\u00adka\u00adsyas\u0131n\u0131n m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. H.pylori, qastrit, m\u0259d\u0259 v\u0259 on\u00adikibarmaq ba\u011f\u0131rsaq xoralar\u0131 v\u0259 m\u0259d\u0259 x\u0259r\u00e7\u0259ngin\u0259 s\u0259b\u0259b ola bil\u0259r. Qeyri-in\u00advazif\u00a0 test oldu\u011fu \u00fc\u00e7\u00fcn m\u00fcalic\u0259y\u0259 ca\u00advab\u0131n m\u00fc\u015fahid\u0259si m\u0259qs\u0259dil\u0259 \u00fcst\u00fcn\u00adl\u00fck verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T A ANT\u0130C\u0130S\u0130M\u0130 IGM (ANT\u0130-HAV IGM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit A anticisimi IgM; HAV IgM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqaiv<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin HAV infeksiya\u00ads\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olu\u00adnur. 15-45 g\u00fcnl\u00fck inkubasiya d\u00f6v\u00adr\u00fcn\u00fc ke\u00e7dikd\u0259n sonra simptomlar\u0131n \u00fcz\u0259 \u00e7\u0131xmas\u0131 il\u0259 birlikd\u0259 qanda tap\u0131l\u0131r v\u0259 ad\u0259t\u0259n pozitivlik 3-6 ay davam edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T A ANT\u0130C\u0130S\u0130M\u0130 TOTAL (ANT\u0130-HAV TOTAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit A anticisiml\u0259ri\u2013 total;\u00a0 HAV total<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>3 saat<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqaiv<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hepatit A-ya qar\u015f\u0131 immunitetin olub-olmad\u0131\u011f\u0131n\u0131n qiy\u00adm\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T B S\u018fTH\u0130 ANT\u0130GEN\u0130 (HBSAG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Hepatit B s\u0259thi (surface) antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya xroniki HBV infeksiyalar\u0131n\u0131n t\u0259yinind\u0259 isti\u00adfad\u0259 olunur. HBV infeksiyas\u0131 zaman\u0131 serumda a\u015fkara \u00e7\u0131xan ilk seroloji markerdir (6-16-c\u0131 h\u0259ft\u0259). K\u0259skin in\u00adfeksiyalarda \u0259sas\u0259n simptomlar it\u00addik\u00ad\u00ad\u00add\u0259n 1-2 ay sonra yox olur. HBsAg-nin 6 aydan \u00e7ox qalmas\u0131 xro\u00ad\u00adniki da\u015f\u0131y\u0131c\u0131l\u0131q v\u0259 ya xroniki qa\u00adraciy\u0259r x\u0259st\u0259liyinin g\u00f6st\u0259ricisidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T B S\u018fTH\u0130 ANT\u0130GEN\u0130N\u018f QAR\u015eI ANT\u0130C\u0130S\u0130M (ANT\u0130-HBS)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbsAb; Hepatit B-nin s\u0259thi antigenin\u0259 qar\u015f\u0131 anticisiml\u0259r; Hepatit B s anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HBV-y\u0259 qar\u015f\u0131 immu\u00adni\u00adtetin t\u0259yinind\u0259 istifad\u0259 olunur. HBV infek\u00adsiyas\u0131n\u0131n bitm\u0259si il\u0259 b\u0259rab\u0259r (HBsAg itdikd\u0259n sonra) anti-HBs \u0259m\u0259l\u0259 g\u0259lir. H\u0259m\u00e7inin HBV-y\u0259 qar\u015f\u0131 immuni\u00adza\u00adsi\u00adyadan (vaksinasiya) son\u00adra immunitetin t\u0259yinind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T B \u00d6Z\u018fK ANT\u0130C\u0130S\u0130M\u0130 IGM (ANT\u0130-HBC IGM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit B virusu \u00f6z\u0259k (core) anticisimi IgM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin HBV infek\u00adsi\u00adya\u00adlar\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olu\u00adnur. Simptomlar\u0131n \u00fcz\u0259 \u00e7\u0131xmas\u0131 il\u0259 b\u0259rab\u0259r qanda tap\u0131l\u0131r. P\u0259nc\u0259r\u0259 d\u00f6v\u00adr\u00fcnd\u0259 serumda tap\u0131lan yegan\u0259 g\u00f6s\u00adt\u0259rici oldu\u011fundan, bu d\u00f6vrd\u0259ki x\u0259s\u00adt\u0259l\u0259rin qiym\u0259tl\u0259ndirilm\u0259si \u00fc\u00e7\u00fcn x\u00fc\u00adsusi \u0259h\u0259miyy\u0259t k\u0259sb edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T B \u00d6Z\u018fK ANT\u0130C\u0130S\u0130M\u0130 TOTAL (ANT\u0130-HBC TOTAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit B virusu \u00f6z\u0259k (core) anticisiml\u0259ri-total<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u018fvv\u0259ll\u0259r HBV infeksi\u00adya\u00ads\u0131n\u0131n ke\u00e7irilib-ke\u00e7irilm\u0259diyi haqq\u0131n\u00adda m\u0259lumat verir. Anti-HBc IgM il\u0259 birlikd\u0259 k\u0259skin\/xroniki HBV infek\u00adsi\u00adyas\u0131n\u0131n diferensial diaqnozu \u00fc\u00e7\u00fcn qiym\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T BE ANT\u0130C\u0130S\u0130M\u0130 (ANT\u0130-HBE)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit B virusu e anti\u00adcisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0HBV infeksiyas\u0131n\u0131n m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. HBeAg itdikd\u0259n sonra serumda tap\u0131l\u0131r. Anti-Hbe pozitiv olan xroniki da\u015f\u0131y\u0131\u00adc\u0131\u00adla\u00adr\u0131n qaraciy\u0259rinin h\u0259m histoloji m\u00fca\u00adyi\u00adn\u0259sinin n\u0259tic\u0259l\u0259ri, h\u0259m d\u0259 funk\u00adsional testl\u0259ri ad\u0259t\u0259n normal olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T BE ANT\u0130GEN\u0130 (HBEAG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u00a0Hepatit Be antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HBV infeksiyas\u0131n\u0131n m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. \u0130nfek\u00adsi\u00adyan\u0131n erk\u0259n d\u00f6vrl\u0259rind\u0259, HBsAg-d\u0259n sonra meydana \u00e7\u0131x\u0131r. Virusda aktiv vi\u00adrus replikasiyas\u0131n\u0131n oldu\u011funu g\u00f6s\u00adt\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T BS ANT\u0130C\u0130S\u0130M\u0130 (ANT\u0130-HBS)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbsAb; Hepatit B-nin s\u0259thi antigenin\u0259 qar\u015f\u0131 anticisiml\u0259r; Hepatit B s anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HBV-y\u0259 qar\u015f\u0131 immu\u00adni\u00adtetin t\u0259yinind\u0259 istifad\u0259 olunur. HBV infek\u00adsiyas\u0131n\u0131n bitm\u0259si il\u0259 b\u0259rab\u0259r (HBsAg itdikd\u0259n sonra) anti-HBs \u0259m\u0259l\u0259 g\u0259lir. H\u0259m\u00e7inin HBV-y\u0259 qar\u015f\u0131 immuni\u00adza\u00adsi\u00adyadan (vaksinasiya) son\u00adra immunitetin t\u0259yinind\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T C ANT\u0130C\u0130S\u0130M\u0130 (ANT\u0130-HCV)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hepatit C anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0HCV infeksiyas\u0131n\u0131n diaq\u00adnos\u00adtikas\u0131nda istifad\u0259 olunur. Ad\u0259t\u0259n HCV infeksiyas\u0131n\u0131n sonrak\u0131 (gec) d\u00f6vr\u00adl\u0259rind\u0259 qanda tap\u0131l\u0131r. Qanda An\u00adti-HCV-nin m\u00f6vcud olmas\u0131 inmmu\u00adni\u00adteti t\u0259min etmir. Pozitiv n\u0259tic\u0259l\u0259r di\u00adg\u0259r m\u00fcayin\u0259 \u00fcsullar\u0131 il\u0259 t\u0259sdiq\u00adl\u0259n\u00adm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEPAT\u0130T D V\u0130RUS ANT\u0130C\u0130S\u0130M\u0130 (ANT\u0130-HDV)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta anticisimi; Anti-Delta ; Hepatit D virusu anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HDV infeksiyas\u0131n\u0131n diaq\u00adnostikas\u0131nda istifad\u0259 olunur. X\u00fcsu\u00adsil\u0259 stabil xroniki HBV infeksiyas\u0131 olanlarda ani k\u0259skinl\u0259\u015fm\u0259 ba\u015f ver\u00addik\u00add\u0259 delta anticisiminin varl\u0131\u011f\u0131 ara\u015f\u00add\u0131r\u0131lmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HERPEKS S\u0130MPLEKS T\u0130P I IGM V\u018f IGG (HSV T\u0130P-1 ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Herpes simplex tip I IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA (seum), IFR (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Yax\u0131n zamanlarda v\u0259 \u0259v\u0259l\u00adl\u0259r ke\u00e7irilmi\u015f HSV tip-1 in\u00adfek\u00adsi\u00adyas\u0131na qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n antici\u00adsim\u00adl\u0259ri m\u00fc\u0259yy\u0259n edir. Tez-tez gingivos\u00adto\u00admatit, herpes labialis, keratit, kon\u00adyuktivit v\u0259 vezikulyar lezyonlara s\u0259\u00adb\u0259b olur. M\u00fcalic\u0259 olunmayan herpes ensefaliti v\u0259 yenido\u011fulmu\u015flar\u0131n her\u00adpes infeksiyas\u0131 70% hallarda\u00a0 fatal n\u0259\u00adtic\u0259l\u0259nir. HSV infeksiyas\u0131nda anti\u00advirus m\u00fcalic\u0259si m\u00fch\u00fcm oldu\u011fundan erk\u0259n diaqnoz \u00e7ox \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HERPES S\u0130MPLEKS T\u0130P II IGM V\u018f IGG (HSV T\u0130P-2 ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Herpes simplex tip II IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA (serum), IFA (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Yax\u0131n zamanlarda v\u0259 ya \u0259v\u0259ll\u0259r ke\u00e7irilmi\u015f HSV tip-2 in\u00adfek\u00adsi\u00adyas\u0131na qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anti\u00adcisim\u00adl\u0259ri m\u00fc\u0259yy\u0259n edir. HSV tip 2 genital herpes\u0259 s\u0259b\u0259b olur. Do\u011fu\u015f zaman\u0131 anadan u\u015fa\u011fa yoluxma ehtimal\u0131 il\u0259 \u0259laq\u0259dar olaraq erk\u0259n diaqnoz \u00e7ox \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HETEROF\u0130L ANT\u0130C\u0130S\u0130M<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u00a0Monospot test<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0EBV infeksiyas\u0131n\u0131n t\u0259yi\u00adnind\u0259 istifad\u0259 olunur. EBV B limfositl\u0259r\u0259 t\u0259sir etdiyind\u0259n spesifik v\u0259 qeyri spesifik anticisim sintezi m\u00fc\u015fahid\u0259 olunur. Testin n\u0259tic\u0259si x\u0259s\u00adt\u0259liyin a\u011f\u0131rl\u0131\u011f\u0131 haqq\u0131nda m\u0259lumat ver\u00admir, lakin titrin artmas\u0131n\u0131n m\u00fc\u00ad\u015fahid\u0259si faydal\u0131d\u0131r. (H\u0259m\u00e7inin Bax\u00a0 EBV IgM v\u0259 IgG profill\u0259ri)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HIV P24 AG + IGG COMBI<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Human immunodeficiency virus\u00a0 p24 antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin HIV infekiyas\u0131 sindromunun t\u0259yinind\u0259 istifad\u0259 olu\u00adnur. Anticisim \u0259m\u0259l\u0259 g\u0259lm\u0259zd\u0259n \u0259v\u00adv\u0259l antigenemiya ba\u015f verdiyi \u00fc\u00e7\u00fcn \u015f\u00fcbh\u0259li t\u0259masdan 3 h\u0259ft\u0259 sonra is\u00adtifad\u0259 oluna bil\u0259r. Pozitiv v\u0259 neqativ n\u0259tic\u0259l\u0259r \u00e7ox diqq\u0259tl\u0259 qiym\u0259tl\u0259n\u00addiril\u00adm\u0259lidir. Pozitiv n\u0259tic\u0259l\u0259r Western blot v\u0259 PZR il\u0259 d\u0259qiql\u0259\u015fdirilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HIV-1 \/ HIV-2 ANT\u0130C\u0130S\u0130M<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u0130nsan\u0131n immun \u00e7at\u0131\u015f\u00admaz\u00adl\u0131q\u00a0(<\/strong>Human immunodeficiency) virus antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA \/ ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00admi\u00adnasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>HIV-in diaqnostikas\u0131nda istifad\u0259 olunur. HIV il\u0259 yoluxmadan sonra, 6-12-ci h\u0259ft\u0259d\u0259n \u0259vv\u0259l po\u00adzi\u00adtiliyi t\u0259yin olunmur. Ad\u0259t\u0259n 6-12-ci h\u0259ft\u0259d\u0259n sonra pozitivl\u0259\u015fir. Q\u0130\u00c7S inki\u015f etdikd\u0259n sonra, x\u0259st\u0259liyin son d\u00f6vrl\u0259rind\u0259 anticisim s\u0259viyy\u0259si t\u0259yin oluna bil\u0259n s\u0259rh\u0259dd\u0259n a\u015fa\u011f\u0131 en\u0259 bi\u00adl\u0259r. Pozitiv v\u0259 neqativ n\u0259tic\u0259l\u0259r \u00e7ox diq\u00adq\u0259tl\u0259 qiym\u0259tl\u0259ndirilm\u0259lidir. Pozi\u00adtiv n\u0259tic\u0259l\u0259r Western blot v\u0259 PZR il\u0259 d\u0259qiql\u0259\u015fdirilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HPSA (HEL\u0130COBACTER PYLOR\u0130 ANT\u0130GEN\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HpSA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a020 g (qoz b\u00f6y\u00fck\u00adl\u00fcy\u00fcnd\u0259)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00f6y\u00fckl\u0259rd\u0259 H.pylorinin t\u0259\u00adyini v\u0259 m\u00fcalic\u0259d\u0259n sonrak\u0131 eradi\u00adka\u00adsyas\u0131n\u0131n m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. H.pylori, qastrit, m\u0259d\u0259 v\u0259 on\u00adikibarmaq ba\u011f\u0131rsaq xoralar\u0131 v\u0259 m\u0259d\u0259 x\u0259r\u00e7\u0259ngin\u0259 s\u0259b\u0259b ola bil\u0259r. Qeyri-in\u00advazif\u00a0 test oldu\u011fu \u00fc\u00e7\u00fcn m\u00fcalic\u0259y\u0259 ca\u00advab\u0131n m\u00fc\u015fahid\u0259si m\u0259qs\u0259dil\u0259 \u00fcst\u00fcn\u00adl\u00fck verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HSV T\u0130P-1 ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Herpes simplex tip I IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA (seum), IFR (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Yax\u0131n zamanlarda v\u0259 \u0259v\u0259l\u00adl\u0259r ke\u00e7irilmi\u015f HSV tip-1 in\u00adfek\u00adsi\u00adyas\u0131na qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n antici\u00adsim\u00adl\u0259ri m\u00fc\u0259yy\u0259n edir. Tez-tez gingivos\u00adto\u00admatit, herpes labialis, keratit, kon\u00adyuktivit v\u0259 vezikulyar lezyonlara s\u0259\u00adb\u0259b olur. M\u00fcalic\u0259 olunmayan herpes ensefaliti v\u0259 yenido\u011fulmu\u015flar\u0131n her\u00adpes infeksiyas\u0131 70% hallarda\u00a0 fatal n\u0259\u00adtic\u0259l\u0259nir. HSV infeksiyas\u0131nda anti\u00advirus m\u00fcalic\u0259si m\u00fch\u00fcm oldu\u011fundan erk\u0259n diaqnoz \u00e7ox \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HSV T\u0130P-2 ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Herpes simplex tip II IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA (serum), IFA (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Yax\u0131n zamanlarda v\u0259 ya \u0259v\u0259ll\u0259r ke\u00e7irilmi\u015f HSV tip-2 in\u00adfek\u00adsi\u00adyas\u0131na qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anti\u00adcisim\u00adl\u0259ri m\u00fc\u0259yy\u0259n edir. HSV tip 2 genital herpes\u0259 s\u0259b\u0259b olur. Do\u011fu\u015f zaman\u0131 anadan u\u015fa\u011fa yoluxma ehtimal\u0131 il\u0259 \u0259laq\u0259dar olaraq erk\u0259n diaqnoz \u00e7ox \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

K\u0130ST H\u0130DAT\u0130K DOLAYI HEMAQQL\u00dc\u00adT\u0130NAS\u0130YA TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Echinococcus seroloji testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Aqql\u00fctinasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Exinokokkoz x\u0259st\u0259liyi \u00fc\u00e7\u00fcn seroloji skrininq testi kimi is\u00adtifad\u0259 olunur. X\u0259st\u0259y\u0259 dair anam\u00adnestik m\u0259lumatlar, klinik simptomlar v\u0259 radioloji m\u0259lumatlara \u0259sas\u0259n diaq\u00adnoz m\u00fc\u0259yy\u0259n edilir. Kollagen to\u00adxuma x\u0259st\u0259likl\u0259ri, sirroz, \u015fisto\u00adsomoz v\u0259 dig\u0259r parazitar infeksiyalar yalan\u00e7\u0131 pozitivlikl\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

K\u0130ST H\u0130DAT\u0130K SPES\u0130F\u0130K IGE<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Echinococcus spesifik IgE<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>FEIA<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Exinokokoz x\u0259st\u0259liyinin diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahi\u00add\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LE\u0130SHMAN\u0130A ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Qeyri d\u00fcz (dolay\u0131) he\u00admaqql\u00fctinasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ley\u015fmaniozun diaqnosti\u00adkas\u0131nda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130STER\u0130A AQQL\u00dcT\u0130NAS\u0130YA TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Listeriozun t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LYME SCREEN (BORREL\u0130A BURGDORFER\u0130 ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Lyme screen (total anticisim)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si.<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Borrelia burqdorferi<\/em>-nin s\u0259b\u0259b oldu\u011fu Lyme x\u0259st\u0259liyinin diaqnozunda istifad\u0259 olunur. X\u0259st\u0259liyin ilkin m\u0259rh\u0259l\u0259sind\u0259 yalan\u00e7\u0131 neqativlik ola bil\u0259r. Anticisiml\u0259rin t\u0259dqiqind\u0259 ilkin n\u0259tic\u0259l\u0259rin neqativ olmas\u0131na baxmayaraq, x\u0259st\u0259liyin ba\u015flan\u011f\u0131c m\u0259rh\u0259l\u0259d\u0259 oldu\u011fu d\u00fc\u015f\u00fc\u00adn\u00fcl\u00fcrs\u0259, 2-4 h\u0259ft\u0259 sonra yeni qan n\u00fcmun\u0259si il\u0259 test t\u0259krarlanmal\u0131d\u0131r. Pozitiv n\u0259tic\u0259l\u0259r is\u0259 Western blot il\u0259 d\u0259qiql\u0259\u015fdirilm\u0259lidir. Sifilis, HIV v\u0259 hiperqammaqlobulinemiya da antici\u00adsim testind\u0259 yalan\u00e7\u0131 pozitivlikl\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MONOSPOT TEST (HETEROF\u0130L ANT\u0130C\u0130S\u0130M)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u00a0Monospot test<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0EBV infeksiyas\u0131n\u0131n t\u0259yi\u00adnind\u0259 istifad\u0259 olunur. EBV B limfositl\u0259r\u0259 t\u0259sir etdiyind\u0259n spesifik v\u0259 qeyri spesifik anticisim sintezi m\u00fc\u015fahid\u0259 olunur. Testin n\u0259tic\u0259si x\u0259s\u00adt\u0259liyin a\u011f\u0131rl\u0131\u011f\u0131 haqq\u0131nda m\u0259lumat ver\u00admir, lakin titrin artmas\u0131n\u0131n m\u00fc\u00ad\u015fahid\u0259si faydal\u0131d\u0131r. (H\u0259m\u00e7inin Bax\u00a0 EBV IgM v\u0259 IgG profill\u0259ri)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MUMPS ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG (PAROT\u0130T ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mumps anticisiml\u0259li IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA \/ ELFA (seum), IFA (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00admi\u00adnasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0IgM k\u0259skin infeksiyan\u0131, IgG is\u0259 t\u0259bii v\u0259 ya vaksinasiya il\u0259 qa\u00adzan\u0131lan immuniteti g\u00f6st\u0259rir. \u0130nku\u00adba\u00adsiya d\u00f6vr\u00fc 18-21 g\u00fcnd\u00fcr. X\u0259st\u0259\u00adliyin ba\u015flamas\u0131ndan 7-14 g\u00fcn sonra anticisim tap\u0131la bil\u0259r. B\u0259zi x\u0259st\u0259l\u0259rd\u0259 t\u0259xmin\u0259n bir il \u0259rzind\u0259 a\u015fa\u011f\u0131 titrd\u0259 pozitiv t\u0259yin olunur. Parotit virusu MSS-\u0259 d\u0259 yoluxa bil\u0259r. Bel\u0259 hallarda BOM-dak\u0131 anticisim s\u0259viyy\u0259si t\u0259yin olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MYCOPLASMA PNEUMONIA IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya ke\u00e7irilmi\u015f Mycoplasma pneumonia infeksi\u00adya\u00ads\u0131na qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259rin t\u0259yinind\u0259 istifad\u0259 olunur. M.pneumo\u00adnia \u0259sas\u0259n birincili atipik pnevmoniyan\u0131n t\u00f6r\u0259dicisidir. IgM v\u0259 IgG-nin h\u0259r ikisinin pozitiv olmas\u0131 yax\u0131n zamanlarda ke\u00e7irilmi\u015f infek\u00adsiyan\u0131, sad\u0259c\u0259 IgG-nin pozitiv olmas\u0131 is\u0259 ke\u00e7irilmi\u015f infeksiyan\u0131 g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u018fC\u0130SD\u018f PARAZ\u0130T ANT\u0130GENL\u018fR\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis (kip qapaql\u0131 qabda, \u0259n gec 24 saat m\u00fcdd\u0259tind\u0259, soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 g<\/p>\n

Testin t\u0259rkibi:<\/strong>\u00a0Giardia antigeni, Entamoeba hystolitica antigeni, Cryptosporidium antigeni, Laz\u0131m g\u0259ldikd\u0259 bu antigenl\u0259rin h\u0259r biri ayr\u0131ca da t\u0259yin oluna bil\u0259r.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0N\u0259cisd\u0259 parazit antigen\u00adl\u0259rinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u018fC\u0130SD\u018f ROTAV\u0130RUS ANT\u0130GEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Rotavirus antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Lateks aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Rotaviruslar yenido\u011ful\u00admu\u015flarda v\u0259 6 ay-2 ya\u015fl\u0131 u\u015faqlarda, x\u00fcsusil\u0259 q\u0131\u015f aylar\u0131nda ishala s\u0259b\u0259b olan \u0259n \u0259h\u0259miyy\u0259tli qeyri-bakterial qastroenterit t\u00f6r\u0259dicil\u0259ridir. Bu viruslara m\u0259xsus antigeninin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PAROT\u0130T ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mumps anticisiml\u0259li IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA \/ ELFA (seum), IFA (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00admi\u00adnasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0IgM k\u0259skin infeksiyan\u0131, IgG is\u0259 t\u0259bii v\u0259 ya vaksinasiya il\u0259 qa\u00adzan\u0131lan immuniteti g\u00f6st\u0259rir. \u0130nku\u00adba\u00adsiya d\u00f6vr\u00fc 18-21 g\u00fcnd\u00fcr. X\u0259st\u0259\u00adliyin ba\u015flamas\u0131ndan 7-14 g\u00fcn sonra anticisim tap\u0131la bil\u0259r. B\u0259zi x\u0259st\u0259l\u0259rd\u0259 t\u0259xmin\u0259n bir il \u0259rzind\u0259 a\u015fa\u011f\u0131 titrd\u0259 pozitiv t\u0259yin olunur. Parotit virusu MSS-\u0259 d\u0259 yoluxa bil\u0259r. Bel\u0259 hallarda BOM-dak\u0131 anticisim s\u0259viyy\u0259si t\u0259yin olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PARVOV\u0130RUS B-19 ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>100\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B 19 infeksiyas\u0131 asimpto\u00admatik v\u0259 ya h\u0259yati t\u0259hl\u00fck\u0259 t\u00f6r\u0259d\u0259n klinik a\u011f\u0131rla\u015fmalarla m\u00fc\u015fahid\u0259 oluna bil\u0259r. U\u015faqlarda tipik s\u0259pkil\u0259rl\u0259 m\u00fc\u00ad\u015fahid\u0259 olunan infeksiya 5-ci x\u0259st\u0259lik d\u0259 adland\u0131r\u0131l\u0131r. M\u00fcv\u0259qq\u0259ti aplastik krizl\u0259r, d\u00f6l\u00fcn hidropsu, artropatiya, m\u00fcxt\u0259lif vaskulyar sindromlar, eri\u00adte\u00adma multiforme v\u0259 eritema nodosum kimi \u0259lam\u0259tl\u0259r\u0259 d\u0259 s\u0259b\u0259b ola bilir. IgM anticisiml\u0259ri virusla t\u0259masdan d\u0259rhal sonra, 7-14-c\u00fc g\u00fcnd\u0259 t\u0259yin olunur, IgG is\u0259 14-c\u00fc g\u00fcnd\u0259n sonra pozitivl\u0259\u015fm\u0259y\u0259 ba\u015flay\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PSEVDOMEMBRANOZ KOL\u0130T SEROLOJ\u0130 TEST\u0130 (CLOSTR\u0130D\u0130UM D\u0130FF\u0130C\u0130LE TOKS\u0130N A)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Psevdomembranoz kolit seroloji testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a020 g<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Clostridium difficile<\/em>,an\u00adtibiotik q\u0259bulu il\u0259 \u0259laq\u0259dar ishal v\u0259 psevdomembranoz kolit\u0259 s\u0259b\u0259b olur. Eyni zamanda A v\u0259 B toksini adlan\u00add\u0131r\u0131lan iki toksin ifraz edir. A toksini maye itkisi, selikli qi\u015falarda z\u0259d\u0259\u00adl\u0259nm\u0259 v\u0259 ba\u011f\u0131rsaq iltihab\u0131na s\u0259b\u0259b olur. A toksininin n\u0259cisd\u0259 tap\u0131lmas\u0131 il\u0259 m\u00f6vcud ishal\u0131n s\u0259b\u0259bi m\u0259lum olur. \u0130shal\u0131n ba\u015flamas\u0131ndan \u0259vv\u0259lki son 8 h\u0259ft\u0259 m\u00fcdd\u0259tind\u0259 antibiotik is\u00adtifad\u0259 ed\u0259nl\u0259r m\u00fctl\u0259q m\u00fcayin\u0259 olunmal\u0131d\u0131rlar. Bir \u00e7ox hallarda\u00a0Clostridium difficile<\/em>\u00a0da\u015f\u0131y\u0131c\u0131l\u0131\u011f\u0131na da rast g\u0259linir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QIZILCA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 (RUBELLA IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0M\u0259xm\u0259r\u0259k anticisimi IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum) Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA (serum), IFA (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0 M\u0259xm\u0259r\u0259k virusu il\u0259 \u0259laq\u0259dar infeksiyan\u0131n varl\u0131\u011f\u0131n\u0131n v\u0259 ehtimal olunan d\u00f6vr\u00fcn\u00fcn t\u0259yinind\u0259 istifad\u0259 olunur. IgM-in pozitiv ol\u00admas\u0131 yeni ba\u015flayan infeksiyan\u0131, k\u00f6h\u00adn\u0259 infeksiyadan qalan qal\u0131q anti\u00adcisiml\u0259r v\u0259 ya vaksinasiya haqq\u0131nda d\u00fc\u015f\u00fcnm\u0259y\u0259 s\u0259b\u0259b olur.Hamil\u0259l\u0259rd\u0259 v\u0259 immun sistemi z\u0259ifl\u0259mi\u015f x\u0259st\u0259l\u0259rd\u0259 a\u011f\u0131r pnevmoniya v\u0259 MSS infeksiyas\u0131na s\u0259b\u0259b ola bil\u0259c\u0259yind\u0259n bu x\u0259st\u0259l\u0259rin m\u0259xm\u0259r\u0259k virusuna qar\u015f\u0131 immunitetin t\u0259yini \u00fc\u00e7\u00fcn an\u00adti\u00adcisiml\u0259r \u0259vv\u0259lc\u0259d\u0259n \u00f6l\u00e7\u00fckm\u0259lidir. \u0130m\u00admun sistemi normal olan u\u015faq\u00adlarda da a\u011f\u0131rla\u015fmalara qar\u015f\u0131 diqq\u0259tli olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QIZILCA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG (RUBELLA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0M\u0259xm\u0259r\u0259k anticisiml\u0259ri IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kon\u00adtaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0M\u0259xm\u0259r\u0259k infeksiyas\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olunur. Rubella virusu u\u015faq v\u0259 b\u00f6y\u00fckl\u0259rd\u0259 y\u00fcng\u00fcl ekzantamatoz x\u0259st\u0259likl\u0259r\u0259 s\u0259b\u0259b olur. \u0130nfeksiyan\u0131n hamil\u0259lik d\u00f6vr\u00fcnd\u0259 ke\u00e7irilm\u0259si \u0259h\u0259miyy\u0259tlidir. Hamil\u0259liyin I tirimesterind\u0259 ke\u00e7iril\u0259n infeksiyalar d\u00f6l\u00fcn ol\u00fcm\u00fcn\u0259 v\u0259 ya anadang\u0259lm\u0259 rubella sindromuna (katarakt, karl\u0131q, \u00fcr\u0259k anomaliyalar\u0131) s\u0259b\u0259b olur. IgG s\u0259viyy\u0259sin\u0259 baxaraq vaksinasiya edil\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RAP\u0130D PLAZMA REAG\u0130N S\u0130F\u0130L\u0130S TEST\u0130 (RPR TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>Rapid plasma reagin sifilis testi; VDRL ekspress test<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sifilisin diaqnozunda istifad\u0259 olunur. K\u0259skin sifilis infeksiyas\u0131 v\u0259 ya aktiv infeksiyan\u0131n ba\u015flan\u011f\u0131c d\u00f6vr\u00fcnd\u0259 test pozitiv olur. M\u00fcnasib m\u00fcalic\u0259 il\u0259 neqativl\u0259\u015fir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RESP\u0130RATOR S\u0130NS\u0130T\u0130AL V\u0130RUS ANT\u0130C\u0130S\u0130ML\u018fR\u0130 (RSV ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Respirator sinsitial virus anticisiml\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Aktiv v\u0259 ya ke\u00e7irilmi\u015f RSV infeksiyas\u0131n\u0131n seroloji \u00fcsulla a\u015fkar edilm\u0259sind\u0259 istifad\u0259 olunur. RSV yeni do\u011fulmu\u015flar\u0131n v\u0259 u\u015faql\u0131q d\u00f6vr\u00fcn\u00fcn a\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131 infeksiyalar\u0131n\u0131n \u0259n \u00e7ox rast g\u0259lin\u0259n t\u00f6r\u0259dicil\u0259rind\u0259ndir. 5 ya\u015f\u0131ndan b\u00f6y\u00fck u\u015faqlarda anticisim ad\u0259t\u0259n pozitiv olur. IgG anticisimi a\u015fa\u011f\u0131 titrd\u0259 d\u0259 tap\u0131l\u0131r, amma IgM anticisimi tap\u0131lmazsa, x\u0259st\u0259 sa\u011falma d\u00f6vr\u00fcnd\u0259 ola bil\u0259r. Bel\u0259 hallarda iki h\u0259ft\u0259 sonra test t\u0259krarlanmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ROTAV\u0130RUS ANT\u0130GEN\u0130 (N\u018fC\u0130SD\u018f ROTAV\u0130RUS ANT\u0130GEN\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Rotavirus antigeni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Lateks aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Rotaviruslar yenido\u011ful\u00admu\u015flarda v\u0259 6 ay-2 ya\u015fl\u0131 u\u015faqlarda, x\u00fcsusil\u0259 q\u0131\u015f aylar\u0131nda ishala s\u0259b\u0259b olan \u0259n \u0259h\u0259miyy\u0259tli qeyri-bakterial qastroenterit t\u00f6r\u0259dicil\u0259ridir. Bu viruslara m\u0259xsus antigeninin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RPR TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>Rapid plasma reagin sifilis testi; VDRL ekspress test<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sifilisin diaqnozunda istifad\u0259 olunur. K\u0259skin sifilis infeksiyas\u0131 v\u0259 ya aktiv infeksiyan\u0131n ba\u015flan\u011f\u0131c d\u00f6vr\u00fcnd\u0259 test pozitiv olur. M\u00fcnasib m\u00fcalic\u0259 il\u0259 neqativl\u0259\u015fir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RSV ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Respirator sinsitial virus anticisiml\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Aktiv v\u0259 ya ke\u00e7irilmi\u015f RSV infeksiyas\u0131n\u0131n seroloji \u00fcsulla a\u015fkar edilm\u0259sind\u0259 istifad\u0259 olunur. RSV yeni do\u011fulmu\u015flar\u0131n v\u0259 u\u015faql\u0131q d\u00f6vr\u00fcn\u00fcn a\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131 infeksiyalar\u0131n\u0131n \u0259n \u00e7ox rast g\u0259lin\u0259n t\u00f6r\u0259dicil\u0259rind\u0259ndir. 5 ya\u015f\u0131ndan b\u00f6y\u00fck u\u015faqlarda anticisim ad\u0259t\u0259n pozitiv olur. IgG anticisimi a\u015fa\u011f\u0131 titrd\u0259 d\u0259 tap\u0131l\u0131r, amma IgM anticisimi tap\u0131lmazsa, x\u0259st\u0259 sa\u011falma d\u00f6vr\u00fcnd\u0259 ola bil\u0259r. Bel\u0259 hallarda iki h\u0259ft\u0259 sonra test t\u0259krarlanmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RUBELLA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0M\u0259xm\u0259r\u0259k anticisiml\u0259ri IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kon\u00adtaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0M\u0259xm\u0259r\u0259k infeksiyas\u0131n\u0131n diaqnostikas\u0131nda istifad\u0259 olunur. Rubella virusu u\u015faq v\u0259 b\u00f6y\u00fckl\u0259rd\u0259 y\u00fcng\u00fcl ekzantamatoz x\u0259st\u0259likl\u0259r\u0259 s\u0259b\u0259b olur. \u0130nfeksiyan\u0131n hamil\u0259lik d\u00f6vr\u00fcnd\u0259 ke\u00e7irilm\u0259si \u0259h\u0259miyy\u0259tlidir. Hamil\u0259liyin I tirimesterind\u0259 ke\u00e7iril\u0259n infeksiyalar d\u00f6l\u00fcn ol\u00fcm\u00fcn\u0259 v\u0259 ya anadang\u0259lm\u0259 rubella sindromuna (katarakt, karl\u0131q, \u00fcr\u0259k anomaliyalar\u0131) s\u0259b\u0259b olur. IgG s\u0259viyy\u0259sin\u0259 baxaraq vaksinasiya edil\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RUBELLA IGG AV\u0130DL\u0130K<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadang\u0259lm\u0259 Rubella sindromu a\u011f\u0131r hallarda s\u0259b\u0259b ola bil\u0259r. \u0130kinci trimesterd\u0259n sonrak\u0131 infeksiyalar d\u00f6l\u0259 t\u0259sir etm\u0259diyind\u0259n infeksiyan\u0131n ba\u015flan\u011f\u0131c tarixi \u00e7ox \u0259h\u0259miyy\u0259tlidir. Avidlik testi il\u0259 Rubella infeksiyas\u0131n\u0131n ba\u015flan\u011f\u0131c tarixi haqq\u0131nda m\u0259lumat \u0259ld\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RUBEOLA IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0M\u0259xm\u0259r\u0259k anticisimi IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum) Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA (serum), IFA (BOM)<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0 M\u0259xm\u0259r\u0259k virusu il\u0259 \u0259laq\u0259dar infeksiyan\u0131n varl\u0131\u011f\u0131n\u0131n v\u0259 ehtimal olunan d\u00f6vr\u00fcn\u00fcn t\u0259yinind\u0259 istifad\u0259 olunur. IgM-in pozitiv ol\u00admas\u0131 yeni ba\u015flayan infeksiyan\u0131, k\u00f6h\u00adn\u0259 infeksiyadan qalan qal\u0131q anti\u00adcisiml\u0259r v\u0259 ya vaksinasiya haqq\u0131nda d\u00fc\u015f\u00fcnm\u0259y\u0259 s\u0259b\u0259b olur.Hamil\u0259l\u0259rd\u0259 v\u0259 immun sistemi z\u0259ifl\u0259mi\u015f x\u0259st\u0259l\u0259rd\u0259 a\u011f\u0131r pnevmoniya v\u0259 MSS infeksiyas\u0131na s\u0259b\u0259b ola bil\u0259c\u0259yind\u0259n bu x\u0259st\u0259l\u0259rin m\u0259xm\u0259r\u0259k virusuna qar\u015f\u0131 immunitetin t\u0259yini \u00fc\u00e7\u00fcn an\u00adti\u00adcisiml\u0259r \u0259vv\u0259lc\u0259d\u0259n \u00f6l\u00e7\u00fckm\u0259lidir. \u0130m\u00admun sistemi normal olan u\u015faq\u00adlarda da a\u011f\u0131rla\u015fmalara qar\u015f\u0131 diqq\u0259tli olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SALMONELLA ANT\u0130C\u0130S\u0130M\u0130 (GRUBER-W\u0130DAL TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qar\u0131n yatala\u011f\u0131 v\u0259 paratif infeksiyalar\u0131 zaman\u0131 O aqql\u00fc\u00adtininl\u0259ri 8-ci g\u00fcnd\u0259n, H aqql\u00fctininl\u0259ri is\u0259 10-12-ci g\u00fcnd\u0259n sonra t\u0259yin oluna bil\u0259n s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. K\u0259skin x\u0259st\u0259liyin t\u0259yini \u00fc\u00e7\u00fcn 10-15 g\u00fcn fasil\u0259 il\u0259 al\u0131nan qan n\u00fcmun\u0259l\u0259rind\u0259 titr art\u0131m\u0131 m\u00fc\u015fahid\u0259 olunmal\u0131d\u0131r. Yaln\u0131z H aqql\u00fctininin olmas\u0131 vaksinasiyan\u0131, O is\u0259 x\u0259st\u0259liyi bildirir. Erk\u0259n m\u0259r\u00adh\u0259\u00adl\u0259d\u0259 m\u00fcalic\u0259y\u0259 ba\u015flan\u0131lan hallarda pozitivlik m\u00fc\u015fahid\u0259 olunmaya bil\u0259r. D\u0259qiq diaqnoz \u00fc\u00e7\u00fcn bu test t\u0259k\u00adba\u00ad\u015f\u0131na yet\u0259rli deyil. Qeyri-spesifik reak\u00adsiyalara da rast g\u0259lin\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

STREP A ANT\u0130GEN TEST\u0130 (D\u00dcZ STREP A TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Strep A antigen testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u018fsn\u0259k material\u0131<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Steril tamponlu s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunoxromatoqrafik<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>A qrupundan olan beta hemolitik streptokoklar\u0131n antigen x\u00fcsusiyy\u0259tl\u0259ri \u0259sas g\u00f6t\u00fcr\u00fcl\u0259r\u0259k bu bakteriyalar t\u0259yin olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOKSOPLAZMA ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Toksoplazma infeksi\u00adya\u00ads\u0131n\u0131n t\u0259yinind\u0259 v\u0259 m\u0259rh\u0259l\u0259sinin a\u015fkar olunmas\u0131nda istifad\u0259 olunur. Kon\u00adge\u00adnital (b\u0259tndaxili) infeksiya riskinin ara\u015fd\u0131r\u0131lmas\u0131nda x\u00fcsusi \u0259h\u0259miyy\u0259t k\u0259sb edir. Hamil\u0259lik zaman\u0131 v\u0259 ya ha\u00admil\u0259likd\u0259n q\u0131sa m\u00fcdd\u0259t \u0259vv\u0259l ke\u00ad\u00e7irilmi\u015f toksoplazma infeksiyalar\u0131 d\u00f6ld\u0259 b\u0259tndaxili anomaliyalara s\u0259b\u0259b ola bilir. \u0130nfeksiyadan sonra IgM bir il v\u0259 ya daha uzun m\u00fcdd\u0259t pozitiv qala bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOKSOPLAZMA ANT\u0130C\u0130S\u0130ML\u018fR\u0130, TOTAL ANT\u0130C\u0130S\u0130M<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Toksoplazma infeksiya\u00ads\u0131n\u0131n t\u0259yini v\u0259 m\u0259rh\u0259l\u0259sinin a\u015fkar\u00adlanmas\u0131nda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOKSOPLAZMA IGG AV\u0130DL\u0130K TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hamil\u0259lik zaman\u0131 ke\u00e7i\u00adri\u00adl\u0259n birincili infeksiya b\u0259tndaxili tok\u00adsoplazmoza s\u0259b\u0259b ola bil\u0259r. Avidlik testi il\u0259 infeksiyan\u0131n 4 aydan daha \u0259v\u00adv\u0259l ba\u015flad\u0131\u011f\u0131n\u0131 t\u0259yin etm\u0259k m\u00fcm\u00adk\u00fcn oldu\u011fundan infeksiyan\u0131n ba\u015f\u00adlan\u011f\u0131c tarixi haqq\u0131nda m\u0259lumat \u0259ld\u0259 edilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TPIHA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TPHA; Treponema pa\u00adllidum hemaqql\u00fctinasiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Qeyri d\u00fcz (dolay\u0131) he\u00admaqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Sifilisin seroloji m\u00fcayi\u00adn\u0259sind\u0259 t\u0259sdiqedici test kimi istifad\u0259 olunur. M\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 \u0259h\u0259miyy\u0259ti yoxdur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TREPONEMA PALL\u0130DUM HEMAGLUT\u0130NAS\u0130YA TEST\u0130 (TP\u0130HA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TPHA; Treponema pa\u00adllidum hemaqql\u00fctinasiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Qeyri d\u00fcz (dolay\u0131) he\u00admaqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Sifilisin seroloji m\u00fcayi\u00adn\u0259sind\u0259 t\u0259sdiqedici test kimi istifad\u0259 olunur. M\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 \u0259h\u0259miyy\u0259ti yoxdur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VAR\u0130CELLA ZOSTER ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG (VZV ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Varicella zoster antici\u00adsiml\u0259ri IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELA\/ELFA\/IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya ke\u00e7irilmi\u015f infeksiyan\u0131n seroloji t\u0259yinind\u0259 isti\u00adfa\u00add\u0259 olunur. S\u0259pkil\u0259r \u0259m\u0259l\u0259 g\u0259ldikd\u0259n 8-10 g\u00fcn sonra IgM tap\u0131la bil\u0259r v\u0259 18-19-cu g\u00fcnl\u0259rd\u0259 pik s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. IgG is\u0259 13-14 g\u00fcn sonra t\u0259yin oluna bil\u0259n s\u0259viyy\u0259y\u0259 \u00e7at\u0131r v\u0259 30-60-c\u0131 g\u00fcnl\u0259rd\u0259 maksimum olur. \u0130mmun sistemi z\u0259ifl\u0259mi\u015f x\u0259st\u0259l\u0259rd\u0259 VZV infeksiyalar\u0131 a\u011f\u0131r ke\u00e7\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VDRL TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Vederal disease research lab testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flokulyasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sifilisin diaqnozunda istifad\u0259 olunan qeyri-spesifik testdir. Erk\u0259n v\u0259 gec d\u00f6vr sifilis lez\u00adyonlar\u0131nda tap\u0131lm\u0131r, eyni zamanda latent subklinik sifilisin diaqnos\u00adtikas\u0131nda da istifad\u0259 olunur. Qeyri-spesifik testl\u0259rd\u0259 al\u0131nan pozitiv n\u0259tic\u0259l\u0259r spesifik \u00fcsullarla d\u0259qiq\u00adl\u0259\u015fdirilm\u0259lidir. H\u0259m\u00e7inin epide\u00admio\u00adloji ara\u015fd\u0131rmalar \u00fc\u00e7\u00fcn \u0259lveri\u015fli testdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VZV ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IGM V\u018f IGG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Varicella zoster antici\u00adsiml\u0259ri IgM v\u0259 IgG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ELA\/ELFA\/IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontaminasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya ke\u00e7irilmi\u015f infeksiyan\u0131n seroloji t\u0259yinind\u0259 isti\u00adfa\u00add\u0259 olunur. S\u0259pkil\u0259r \u0259m\u0259l\u0259 g\u0259ldikd\u0259n 8-10 g\u00fcn sonra IgM tap\u0131la bil\u0259r v\u0259 18-19-cu g\u00fcnl\u0259rd\u0259 pik s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. IgG is\u0259 13-14 g\u00fcn sonra t\u0259yin oluna bil\u0259n s\u0259viyy\u0259y\u0259 \u00e7at\u0131r v\u0259 30-60-c\u0131 g\u00fcnl\u0259rd\u0259 maksimum olur. \u0130mmun sistemi z\u0259ifl\u0259mi\u015f x\u0259st\u0259l\u0259rd\u0259 VZV infeksiyalar\u0131 a\u011f\u0131r ke\u00e7\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

WE\u0130L-FEL\u0130X TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Aqql\u00fctinasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Proteus<\/em>\u00a0cinsli bakteri\u00adya\u00adlar\u0131n\u0131n Rikketsiyalarla ortaq anti\u00adgenl\u0259r da\u015f\u0131y\u0131r. Buna \u0259saslanaraq rikketsiya anticisiml\u0259rinin varl\u0131\u011f\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section><\/div>[\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15883","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/comments?post=15883"}],"version-history":[{"count":2,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15883\/revisions"}],"predecessor-version":[{"id":15923,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15883\/revisions\/15923"}],"wp:attachment":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/media?parent=15883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}